Showing 541-550 of 1310 results for "".
- Sirnaomics Gets FDA Go Ahead to Move STP705 Into Late-Stage Clinical Development for isSCChttps://practicaldermatology.com/news/sirnaomics-gets-fda-go-ahead-to-move-stp705-into-late-stage-clinical-development-for-isscc/2461788/Sirnaomics Ltd.’s STP705 for the treatment of Squamous Cell Carcinoma in situ (isSCC) is moving into late-stage clinical development after encouraging Phase IIa and Phase IIb clinical results. These results were shared with the U.S. Food and Drug Administration (FDA) in an En
- FDA Nod for Avita Medical’s RECELL for Skin Repigmentation in Vitiligo Patientshttps://practicaldermatology.com/news/fda-nod-for-avita-medicals-recell-for-skin-repigmentation-in-vitiligo-patients/2461787/The U.S. Food and Drug Administration (FDA) has approved AVITA Medical, Inc.’s application for premarket approval (PMA) of its RECELL System for the treatment of vitiligo. RECELL for repigmentation of stable depigmented vitiligo lesions is the first FDA-approved therapeutic d
- EAACI News: Barzolvolimab May Help Tame Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/eaaci-news-barzolvolimab-may-help-tame-chronic-spontaneous-urticaria/2461786/Celldex Therapeutics, Inc.’s barzolvolimab is looking good in chronic spontaneous urticaria, according to data from the Phase 1b single-dose cholinergic cohort included in the chronic inducible urticaria (CIndU) trial that was presented at the European Academy of Allergy and Clini
- Cutera's AviClear Scores FDA Nod as Long-Term Acne Treatmenthttps://practicaldermatology.com/news/cuteras-aviclear-scores-fda-nod-as-long-term-acne-treatment/2461784/The U.S. Food and Drug Administration (FDA) has cleared AviClear as a long-term treatment for mild to severe inflammatory acne vulgaris. Cutera’s AviClear initially received FDA clearance for treating acne in March 2022. Now, the FDA has cleared the device for the long
- Gentle Cleansers Kill Viruses as Effectively as Harsh Soapshttps://practicaldermatology.com/news/gentle-cleansers-kill-viruses-as-effectively-as-harsh-soaps/2461780/Gentle cleansers are just as effective in killing viruses – including coronavirus - as harsh soaps, a new study out University of Sheffield experts has found. Scientists from the University of Sheffield’s Sh
- And the Winners Are…Botox Cosmetic Announces the Winners of the IFundWomen Grant Programhttps://practicaldermatology.com/news/and-the-winners-arebotox-cosmetic-announces-the-winners-of-the-ifundwomen-grant-program/2461779/Twenty female entrepreneurs will receive funding and mentorship through Allergan’s BOTOX Cosmetic and IFundWomen grant program. "There were so many remarkable applications that featured thoughtful business solutions," says Carrie Strom, President, Global Aller
- Fall Clinical PAs & NP Update: Castle's DecisionDx-SCC Can Identify Tumors Likely to Spread in Low-Risk CSCChttps://practicaldermatology.com/news/fall-clinical-pas-np-update/2461778/Castle Biosciences, Inc.’s DecisionDx-SCC test can identify tumors likely to metastasize in patients with cutaneous squamous cell carcinoma deemed low risk by traditional staging, according to research presented at the the 2023 Fall Clinical Dermatology Conference for PAs &am
- Highly Trafficked Roads Up AD Risk in Kids, Teenshttps://practicaldermatology.com/news/highly-trafficked-roads-up-ad-risk-in-kids-teens/2461772/Traffic-related air pollution may increase children and teen’s risk for atopic dermatitis report researchers at National Jewish Health in Denver, Colo. For the study, researchers reviewed charts of patients 0-18 years of age who had been seen at National Jewish Health i
- Biosimilar Update: Dr. Reddy’s Completes Phase I Study of Proposed Tocilizumab Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-dr-reddys-completes-phase-i-study-of-proposed-tocilizumab-biosimilar/2461765/Dr. Reddy’s Laboratories’ tocilizumab biosimilar candidate, DRL_TC, met its primary and secondary endpoints in a Phase I study. The company is now initiating a global Phase III study with the aim of comparing the efficacy, safety, tolerability and immunogeni
- Sol-Gel, Searchlight Pharma Partner to Commercialize TWYNEO and EPSOLAY in Canadahttps://practicaldermatology.com/news/sol-gel-searchlight-pharma-partner-to-commercialize-twyneo-and-epsolay-in-canada/2461764/Israel’s Sol-Gel Technologies, Ltd. and Searchlight Pharma Inc. have signed exclusive license agreements for TWYNEO and EPSOLAY for the Canadian market. Both products recently launched in the U.S., and Searchlight is to commercialize in Canada over a fifteen-year term that i